Spinal muscular atrophy (SMA) is one of the leading genetic diseases of children and infants. SMA is caused by deletions or mutations of Survival Motor Neuron 1 (SMN1) gene. SMN2, a nearly identical copy of SMN1, cannot compensate for the loss of SMN1 due to predominant skipping of exon 7. While various regulatory elements that modulate SMN2 exon 7 splicing have been proposed, intronic splicing silencer N1 (ISS-N1) has emerged as the most promising target thus far for antisense oligonucleotide-mediated splicing correction in SMA. Upon procuring exclusive license from the University of Massachussets Medical School in 2010, Ionis Pharmaceuticals (formerly ISIS Pharamaceuticals) began clinical development of Spinraza™ (synonyms: Nusinersen, IONIS-SMN RX , ISIS-SMN RX ), an antisense drug based on ISS-N1 target. Spinraza™ showed very promising results at all steps of the clinical development and was approved by US Food and Drug Administration (FDA) on December 23, 2016. Spinraza™ is the first FDA-approved treatment for SMA and the first antisense drug to restore expression of a fully functional protein via splicing correction. The success of Spinraza™ underscores the potential of intronic sequences as promising therapeutic targets and sets the stage for further improvement of antisense drugs based on advanced oligonucleotide chemistries and delivery protocols.
Introduction
Spinal muscular atrophy (SMA) is the leading genetic cause of infant mortality [1] . SMA is characterized by the degeneration of a-motor neurons in the spinal cord, leading to progressive muscle weakness followed by respiratory insufficiency [1, 2] . SMA is caused by low levels of Survival Motor Neuron SMA is unique among genetic disorders in that humans carry a second copy of the SMN gene, SMN2 [3, 6] . However, due to a translationally silent C-to-T mutation (C6U in RNA) at the 6 th position of exon 7, SMN2 exon 7 is inefficiently spliced producing a truncated protein SMN∆7, which is unstable and only partially functional [6, 7, 8] . While several additional splice isoforms are generated by alternative splicing of both SMN1 and SMN2 [9-12], transcripts lacking exon 7 appear to be the major isoform produced by SMN2 in all tissues except in testis [10, 13] . Therefore, mechanism of SMN2 exon 7 splicing has been intensively studied [14] [15] [16] [17] [18] [19] [20] [21] . Due to the potential for SMN2 to produce full-length SMN protein, it remains the principal target for therapies designed to increase production of functional SMN protein in conditions of SMA [22, 23, 24] .
Discovery of ISS-N1 as potential therapeutic target
Multiple approaches have been explored as potential methods to increase production of SMN protein from SMN2, including increasing transcription [22, 24, 25, 26] , modulating SMN2 exon 7 splicing [27] [28] [29] [30] , inducing translational read through of SMN∆7 transcript [31] , and increasing stability of SMN protein [32, 33] .
One of the most promising methods is the redirection of SMN2 splicing of exon 7 through antisense oligonucleotides (ASOs), short oligonucleotides designed to anneal to complementary sequences within a gene of interest [30, 34] . ASOs can exert their influence on SMN2 exon 7 splicing through multiple ways, including but not limited to blocking binding of trans-acting protein factors by steric hindrance [35, 36] , causing structural rearrangements within the target RNA molecule [37, 38, 39] , or recruiting additional trans-acting protein factors to the target molecule, in the case of bifunctional ASOs [40, 41, 42] . Translational Neuroscience
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